Analyst Report: GL
1. EXECUTIVE SUMMARY
Globe Life fell 8.09% to $154.79 on Friday October 23, 2026, after Piper Sandler downgraded the shares to Neutral from Overweight and cut its price target to $165 from $200. The downgrade followed third-quarter results released after the close on October 21, which came with a lower full-year 2026 operating EPS range, driven by losses at the Evry group health unit and excess Medicare Supplement claims. Volume on the two sessions after the report ran at 1,736,100 and 1,651,200 shares, against a 50-session average of 464,750. Management's 2027 guidance sits above the consensus cited by TIKR, so the debate centres on whether claims volatility settles over the next several quarters. The stock now trades at 9.4 times forward earnings, and the move leaves it below both its 50-day and 200-day averages.
2. THE CATALYST
The move came in two steps.
Step one, results. Globe Life reported Q3 results after the close on Wednesday October 21 and cut its 2026 operating EPS range to $15.35–$15.65 from $15.55–$15.95 (company press release, October 21). The company attributed the cut to an underwriting loss of about $16 million at Evry and roughly $7 million of excess Medicare Supplement claims tied to a CMS processing delay (press release; Yahoo Finance/StockStory, October 22). Q3 operating EPS was $4.84 against a consensus cited by TIKR as $4.89, and revenue of $1.61bn, up 6% year on year, was in line with estimates (TIKR; Yahoo Finance, October 23). Premium revenue grew about 7%.
Step two, downgrade. On October 23, Piper Sandler analyst Paul Newsome moved to Neutral and cut the target to $165 (TIKR; Investing.com, October 23). He argued that Globe Life is no longer a predictable safe haven in life insurance, citing larger medical claims where reinsurance still leaves volatility, irregular Medicare Supplement claims expected for several more quarters, and softer 2027 guidance for the core business. Piper also noted that rivals are tightening underwriting and pushing for higher rates, which could leave Globe Life with riskier customers in its Medicare-related growth push (Investing.com).
| Session | Close | Change | Volume |
|---|---|---|---|
| Oct 21 (results after close) | $169.62 | -0.06% | 472,500 |
| Oct 22 | $168.41 | -0.71% | 1,736,100 |
| Oct 23 (Piper downgrade) | $154.79 | -8.09% | 1,651,200 |
Shares fell in the morning of October 22, and StockStory reported an intraday decline, but the session closed down only 0.71%. The decline then took hold on October 23, when the stock opened at $166.06 and traded as low as $154.09.
3. COMPANY PROFILE
Globe Life Inc. is a Financial Services company in life insurance. Through its subsidiaries it sells life and supplemental health insurance to lower middle- and middle-income families in the United States, across Life Insurance, Supplemental Health Insurance and Investments segments. Products include whole and term life, children's life cover, Medicare supplement and limited-benefit health policies. Market peers in life and health insurance include MetLife, Prudential, Aflac and Principal.
Recent guidance from the Q3 call (Yahoo Finance and Motley Fool, October 22):
- 2027 operating EPS of $16.10–$17.10, a 7% increase at the midpoint, with roughly 5–6 points coming from buybacks.
- 2027 health underwriting margin of 20–24% of premiums, with margin dollars growing 7–9%.
- 2027 health premium revenue growth of 13–15%, supported by Medicare Supplement and Evry rate actions.
- Parent excess cash flow of $850–950 million in 2027 (Benzinga transcript).
Management expects Evry's high-severity claims to improve in Q4, though loss ratios stay above target for the rest of 2026 (Benzinga transcript). The CMS-related claims are expected to normalize.
4. DEEP DIVE ANALYSIS
Do fundamentals justify the move? The quarterly miss was small: $4.84 against $4.89 in the TIKR figures, though sources disagree on the consensus and on whether revenue met or missed. The 2026 guidance cut of $0.20 at the midpoint is larger, and the Piper downgrade changed the framing from one bad quarter to a loss of earnings predictability. The 8.09% fall on the downgrade day, after only a 0.71% decline on the day after results, indicates that investors treated the analyst's reasoning as new information. Whether the full decline is deserved is a judgement call. The 2027 guidance midpoint is about $16.60, while TIKR cites 2027 consensus of $16.45, so consensus already sits below management's range midpoint.
Valuation. Before the drop the stock traded near 11x forward earnings, close to its five-year average of about 10x (TIKR). The forward P/E in the facts is now 9.4, and the trailing P/E is 10.4.
Peers. The brief links the decline to no peer-specific event. Over the same period MET fell 4.59%, PRU 2.69%, AFL 2.24% and PFG 1.40%, against a 0.52% decline in the S&P 500. On October 22, a sharp Treasury rally (10-year yield down about 18.5 basis points) and a Nasdaq drop tied to Meta's cash-flow news shaped the macro backdrop (24/7 Wall St.). As inference, falling yields likely contributed to the weakness in life insurers, though the brief does not establish this. Globe Life's drop is well beyond the peer range.
Comparable episodes. About three months earlier the shares fell about 7% after Q2 2026 results, though sources conflict on whether that quarter was in line (StockStory) or a $0.06 EPS miss with a guidance midpoint below consensus (Investing.com). A year earlier, a Q2 2025 beat and guidance raise produced a gain of about 5.6% (StockStory). Two sharp declines in one quarter reinforce Piper's point about predictability.
Bull case. Management guides to 7% EPS growth in 2027, with 13–15% health premium growth and a $2.5 billion buyback authorization (MarketBeat). TD Cowen kept Buy and cut its target to $215 from $225. MarketBeat consensus, as cited by Cerbat Gem, is Moderate Buy with a $182.60 target across 1 Strong Buy, 7 Buy and 3 Hold ratings. The shares are now below the Piper target of $165 and well below the consensus target.
Bear case. Claims irregularity is expected to persist for several quarters (Piper). Rate filings that address the higher claims trend take effect in 2Q27 only if approved (Yahoo Finance). Insiders sold roughly $25.8 million over the prior 90 days (MarketBeat). Piper's concern about adverse selection in Medicare-related growth is unresolved.
5. TECHNICAL SNAPSHOT
The close of $154.79 sits below the 50-day average of $169.83 and below the 200-day average of $158.74, having broken through the longer average on heavy volume. The 52-week range runs from $126.81 to $191.17, so the shares are 19.0% below the high and well above the low. Volume of 1,651,200 was 3.55x the 50-session average, and the prior session's 1,736,100 was larger still, which indicates broad repositioning. The latest close is the lowest in the ten-session table, so no nearby support level exists in the data. The nearest resistance is $165.12, the October 12 close, followed by the 200-day average at $158.74.
6. RISK FACTORS
- Further claims surprises at Evry or in Medicare Supplement, since loss ratios are guided to stay above target through 2026.
- Rate filings for Medicare Supplement and Evry take effect in 2Q27 only if approved, which is the main regulatory checkpoint (Benzinga transcript).
- Competitors tightening underwriting could leave Globe Life with riskier business (Piper).
- Additional analyst target cuts. A UBS $165 objective appears in only one weak source and is unconfirmed.
- Continued insider selling.
- The next earnings report, covering Q4 and full-year 2026, is expected early in 2027. The date is not in the sources.
7. ACTIONABLE OUTLOOK
Short term (1-2 weeks). The shares have fallen 8.28% over five sessions, and the stock sits below its 200-day average. The $158.74 average and $165.12 close are the levels to watch. Further analyst revisions and any company commentary on Q4 claims would drive direction.
Medium term (1-3 months). Evidence on Evry's high-severity claims in Q4 and progress on the 2Q27 rate filings will determine whether the predictability argument holds. A 9.4x forward multiple against a roughly 10x five-year average prices in some continued volatility. Consensus 2027 EPS below the guidance midpoint leaves room for a recovery if claims normalise, while a repeat of the Q2 and Q3 pattern would extend the decline.
Long term. The thesis of steady growth in low and middle-income life and supplemental health is intact in management's 2027 guidance and buyback capacity. What has changed is confidence in earnings predictability, and that confidence returns through several clean quarters. This is analysis only and not personal financial advice.